U.S. Markets closed
  • S&P Futures

    4,084.75
    +3.50 (+0.09%)
     
  • Dow Futures

    34,585.00
    -14.00 (-0.04%)
     
  • Nasdaq Futures

    12,049.25
    +7.00 (+0.06%)
     
  • Russell 2000 Futures

    1,891.50
    +4.00 (+0.21%)
     
  • Crude Oil

    80.64
    +0.09 (+0.11%)
     
  • Gold

    1,790.00
    +30.10 (+1.71%)
     
  • Silver

    22.47
    +0.68 (+3.14%)
     
  • EUR/USD

    1.0434
    +0.0026 (+0.2504%)
     
  • 10-Yr Bond

    3.7030
    -0.0450 (-1.20%)
     
  • Vix

    20.58
    -1.31 (-5.98%)
     
  • GBP/USD

    1.2090
    +0.0028 (+0.2309%)
     
  • USD/JPY

    136.6960
    -1.3840 (-1.0023%)
     
  • BTC-USD

    17,134.29
    +285.59 (+1.70%)
     
  • CMC Crypto 200

    406.23
    +5.53 (+1.38%)
     
  • FTSE 100

    7,573.05
    +61.05 (+0.81%)
     
  • Nikkei 225

    28,278.66
    +309.67 (+1.11%)
     

Xenon Pharmaceuticals to Present at the 13th Annual Wedbush PacGrow Healthcare Conference

Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc.

BURNABY, British Columbia, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in virtual one-on-one investor meetings and a fireside chat presentation at the 13th Annual Wedbush PacGrow (Virtual) Healthcare Conference.

Fireside Chat Details:

 

 

 

Date:

Wednesday, August 10, 2022

 

 

Time:

2:55-3:25 pm ET

 

 

Presenters:

Ian Mortimer, President and CEO

 

Sherry Aulin, CFO

A webcast of the fireside chat will be available on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com